Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a research report issued on Monday, November 6th.
A number of other research analysts also recently issued reports on SBPH. Cantor Fitzgerald started coverage on Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They set an “overweight” rating and a $29.00 target price for the company. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Finally, B. Riley started coverage on Spring Bank Pharmaceuticals in a report on Monday, November 6th. They set a “buy” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $27.25.
Spring Bank Pharmaceuticals (SBPH) traded up $0.11 during midday trading on Monday, hitting $15.29. The stock had a trading volume of 18,296 shares, compared to its average volume of 45,119. Spring Bank Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $18.93.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.